Skip to main content
. 2016 Dec 13;18:294. doi: 10.1186/s13075-016-1190-z

Fig. 2.

Fig. 2

Association between the four explanatory variables and EULAR response at 24 weeks after the first rituximab infusion in the combination of cohorts 1 and 2. Results from the multivariate analysis are presented as odds ratios (OR) (95% confidence intervals (CI)) for each factor. anti-CCP anti-cyclic citrullinated peptide antibody, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, IL interleukin, RF rheumatoid factor